» Articles » PMID: 27127546

ROS-Mediated NLRP3 Inflammasome Activation in Brain, Heart, Kidney, and Testis Ischemia/Reperfusion Injury

Abstract

Ischemia and reperfusion (I/R) causes a reduction in arterial blood supply to tissues, followed by the restoration of perfusion and consequent reoxygenation. The reestablishment of blood flow triggers further damage to the ischemic tissue through reactive oxygen species (ROS) accumulation, interference with cellular ion homeostasis, and inflammatory responses to cell death. In normal conditions, ROS mediate important beneficial responses. When their production is prolonged or elevated, harmful events are observed with peculiar cellular changes. In particular, during I/R, ROS stimulate tissue inflammation and induce NLRP3 inflammasome activation. The mechanisms underlying the activation of NLRP3 are several and not completely elucidated. It was recently shown that NLRP3 might sense directly the presence of ROS produced by normal or malfunctioning mitochondria or indirectly by other activators of NLRP3. Aim of the present review is to describe the current knowledge on the role of NLRP3 in some organs (brain, heart, kidney, and testis) after I/R injury, with particular regard to the role played by ROS in its activation. Furthermore, as no specific therapy for the prevention or treatment of the high mortality and morbidity associated with I/R is available, the state of the art of the development of novel therapeutic approaches is illustrated.

Citing Articles

Regulation of BzATP-Induced Blood-Brain Barrier Endothelial Cell Hyperpermeability by NLRP3 Inflammasome Inhibition.

Anderson A, Waithe O, Seplovich G, Olagunju O, Greene C, Singh A Microcirculation. 2025; 32(3):e70006.

PMID: 40052959 PMC: 11905927. DOI: 10.1111/micc.70006.


Myrtenal Pretreatment Exerts a Protective Effect Against Renal Ischemia-Reperfusion Injury in Rats.

Beytur L, Korkmaz E, Kose E, Taslidere A, Tekin S J Biochem Mol Toxicol. 2025; 39(3):e70202.

PMID: 40025781 PMC: 11873678. DOI: 10.1002/jbt.70202.


Frontiers and Hotspot Evolution of NLRP3 Inflammasome in Myocardial Infarction Research: A Bibliometric Analysis From 2013 to 2024.

Wu J, Lan Q, Zhang D, Jian Y, Yu L, Hao R Cardiovasc Ther. 2025; 2025:5178894.

PMID: 40018377 PMC: 11865457. DOI: 10.1155/cdr/5178894.


NOX4 Regulates NLRP3 by Inhibiting the Ubiquitination of LRRC8A to Promote Ferroptosis in Nucleus Pulposus Cells.

Zhang F, Cui D, Wang Z, Li Y, Wang K, Lu H Inflammation. 2025; .

PMID: 39909992 DOI: 10.1007/s10753-025-02253-0.


Deciphering Oxidative Stress in Cardiovascular Disease Progression: A Blueprint for Mechanistic Understanding and Therapeutic Innovation.

Zhang Z, Guo J Antioxidants (Basel). 2025; 14(1).

PMID: 39857372 PMC: 11759168. DOI: 10.3390/antiox14010038.


References
1.
Shao B, Xu Z, Han B, Su D, Liu C . NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015; 6:262. PMC: 4633676. DOI: 10.3389/fphar.2015.00262. View

2.
Pomerantz B, Reznikov L, Harken A, Dinarello C . Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A. 2001; 98(5):2871-6. PMC: 30232. DOI: 10.1073/pnas.041611398. View

3.
Niu L, Zhang S, Wu J, Chen L, Wang Y . Upregulation of NLRP3 Inflammasome in the Tears and Ocular Surface of Dry Eye Patients. PLoS One. 2015; 10(5):e0126277. PMC: 4427105. DOI: 10.1371/journal.pone.0126277. View

4.
Tirapelli L, Barione D, Trazzi B, Tirapelli D, Novas P, Silva C . Comparison of two models for evaluation histopathology of experimental renal ischemia. Transplant Proc. 2009; 41(10):4083-7. DOI: 10.1016/j.transproceed.2009.09.061. View

5.
Wu H, Craft M, Wang P, Wyburn K, Chen G, Ma J . IL-18 contributes to renal damage after ischemia-reperfusion. J Am Soc Nephrol. 2008; 19(12):2331-41. PMC: 2588109. DOI: 10.1681/ASN.2008020170. View